AllianceBernstein’s Apyx Medical APYX Stock Holding History

AllianceBernstein’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$65K	–	3264
2022 Q1	$65K	Sell	10,000 -9,922	-50%	-$97.7K	﹤0.01%	3151
2021 Q4	$255K	Buy	19,922 +9,922	+99%	+$139K	﹤0.01%	2991
2021 Q3	$139K	Hold	10,000	–	–	﹤0.01%	3153
2021 Q2	$103K	Buy	+10,000	New	+$99.1K	﹤0.01%	3241

Other funds holding APYX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Invenire Partners Ridgefield, Connecticut $65.4M AUM 18.1% 1-Year Est. Return

AllianceBernstein's APYX Position: Q2 2022 in Review

AllianceBernstein sold out of Apyx Medical (APYX) in Q2 2022, closing a stake of 10,000 shares — an estimated $65K sold.

AllianceBernstein first reported a position in APYX in Q2 2021 and held it in 4 quarters. The position peaked at $255K in Q4 2021. 63 funds tracked by Wall St. Rank hold APYX as of Q2 2022.

AllianceBernstein reported no remaining Apyx Medical position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 10,000 Apyx Medical shares in Q2 2022, an estimated $65K.
AllianceBernstein first reported a position in Apyx Medical in Q2 2021 and held it in 4 quarters.
AllianceBernstein's Apyx Medical position peaked at $255K in Q4 2021.
63 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.